Search

Indicated for BRAF V600E mutant anaplastic thyroid cancer.

​As add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.

For the treatment of generalized myasthenia gravis (gMG) in adult patients.

For the treatment of moderate-to-severe prurigo nodularis (PN).

Pombiliti (cipaglucosidase alfa for injection) is indicated in combination with the enzyme stabiliser Opfolda (65 mg miglustat capsule) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Opfolda (miglustat capsules) is an enzyme stabilizer indicated in combination with Pombiliti (cipaglucosidase alfa) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥40 kg.

​Dupixent is indicated for the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

​Keytruda as monotherapy is indicated for the adjuvant treatment of adult patients with Stage IB (T2a greater than or equal to 4 cm), II, or IIIA NSCLC who have undergone complete resection and platinum-based chemotherapy.

Sarclisa (isatuximab for injection) is indicated in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).